SCHEMBL19508035

SCHEMBL19508035

Cc1cc2c(cn1)cc(C)c(=O)n2C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 7/20 0.47
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FGFR1 P11362 7/20 0.40
SRC P12931 7/20 0.40
CYP1A2 P05177 1/20 0.37
CYP2A6 P11509 1/20 0.37
BRD1 O95696 5/20 0.36
BRPF3 Q9ULD4 4/20 0.36
UHRF1 Q96T88 1/20 0.34
BRD4 O60885 3/20 0.33
BRD9 Q9H8M2 2/20 0.33
BRD7 Q9NPI1 1/20 0.33
AAK1 Q2M2I8 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30480859 0.80 BRPF1 (0.43) BRPF1KDM4EALDH1A1GLAHPGD
SCHEMBL502548 0.76 SRC (0.47) BRPF1ALDH1A1FGFR1SRC
SCHEMBL30754455 0.75 BRPF1 (0.47) BRPF1KDM4EFGFR1SRCCYP1A2
SCHEMBL27383191 0.75 AHR (0.35) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL27383051 0.75 RIPK2 (0.45) FGFR1SRC
SCHEMBL14145303 0.74 SRC (0.40) KDM4EFGFR1SRCCYP2A6
SCHEMBL10813893 0.74 BRPF1 (0.54) BRPF1KDM4EALDH1A1GLAHPGD
SCHEMBL19508038 0.74 ALDH1A1 (0.62) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL24665079 0.74 FGFR1 (0.45) FGFR1SRCBRD4
SCHEMBL502525 0.73 MAPK14 (0.53) KDM4EALDH1A1HPGDFGFR1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305918-A1 DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 NEWAVE PHARMACEUTICAL INC. 2017-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305918-A1 DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 FGFR4, FGFR2, FGFR3 BRPF1 839/4885KDM4E 214/4885ALDH1A1 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.